Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry – ANNALS OF THE RHEUMATIC DISEASES

by | Jan 1, 2024 | Publicaciones - D-03 | 0 comments

Hernández-Cruz, B; Otero-Varela, L; Freire-González, M; Busquets-Pérez, N; González, AJG; Moreno-Ramos, M; Blanco-Madrigal, JM; Manrique-Arija, S; Perez-Pampin, E; Ruiz-Montesino, D; Sánchez-Alonso, F; Sanchez-Piedra, C; Castrejón, I – 2024 – 10.1136/ard-2023-225271